Oppenheimer initiated coverage on Fusion Pharmaceuticals Inc FUSN, citing the company's pipeline as among the best in the space with alpha-emitter-based targeted radionuclide therapies (TRTs), with three currently in clinical development. The analysts Jeff Jones and Kyle Yang have initiated with…
#oppenheimer #jeffjones #kyleyang #mcrpc #phase2 #novartisag #nvs #fusn
Continue reading...